Ultrastructural damage in vascular endothelium in rats treated with paclitaxel and doxorubicin

Ultrastructural Pathology

Volumn 30, Issue 1-2, 2006, Pages 103-110

  Yamaç, Deniz ^a,c   Elmas, Çiǧdem ^a   Özoǧul, Candan ^a   Keskil, Zuhal ^b   Dursun, Ayşe ^a  

^a GAZI UNIVERSITY   (Turkey)

^b KIRIKKALE UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Doxorubicin; Endothelium damage; Paclitaxel; Ultrastructure

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORPHENOXAMINE; CREMOPHOR; DEXAMETHASONE; DOXORUBICIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; PACLITAXEL; RANITIDINE; STEROID; ANTINEOPLASTIC ANTIBIOTIC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; BASEMENT MEMBRANE; CARDIOTOXICITY; CELL MEMBRANE; CELL NUCLEUS; CELL VACUOLE; CONFERENCE PAPER; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; HYPERSENSITIVITY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RIBOSOME; ULTRASTRUCTURE; ANIMAL; ARTICLE; CELL ORGANELLE; DRUG COMBINATION; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; METHODOLOGY; TRANSMISSION ELECTRON MICROSCOPY; VASCULAR ENDOTHELIUM; WISTAR RAT;

ANIMALIA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AORTA; CELL NUCLEUS; DOXORUBICIN; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; INJECTIONS, INTRAPERITONEAL; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; ORGANELLES; PACLITAXEL; RATS; RATS, WISTAR;

EID: 33646008619     PISSN: 01913123     EISSN: 15210758     Source Type: Journal    
DOI: 10.1080/01913120500406335     Document Type: Conference Paper

References (25)

1. Drouet L, Baudin B. Comment l'endothelium participate-t-il au controle du tonus vascularite? Rev Prat. 1988;38:2090-2094.
2. Davies MG, Hagen PO. The vascular endothelium: a new horizon. Ann Surg. 1993;218:593-609.
3. Pearson JD. The control of production and release of haemostatic factors in endothelial cells. Ballieres Clin Haematol. 1993;161:155-167.
4. Lazo JS, Lynch TJ, McCalister J. Bleomycin inhibition of angiotensin-converting enzyme activity from serum, lungs and cultured pulmonary artery endothelial cells. Am Rev Respir Dis. 1986;134:74-78.
5. Czaykowiski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urethelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160:1021.
6. Smith AC, Boyd MR. Effects of bis-chloronitrosourea (BCNU) on pulmonary and serum angiotensin-converting enzyme activity in rats. Biochem Pharmacol. 1989;32:3719-3722.
7. Adamson IYR, Orr FW, Young L. Effects of injury and repair of the pulmonary endothelium on lung metastasis after bleomycin. J Pathol. 1986;150:279-287.
8. Arbuck SG, Strauss H, Rowinsky E. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr. 1993;15:117-130.
9. Roth BJ, Yeap BY, Wilding G, Kasimis B, McLeod D, Loehrer PJ. Taxol in advanced, hormone-refractory carcinoma of the prostate: a phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72:2457-2460.
10. Rowinski EK, Donehower RC. Drug therapy: Paclitaxel (Taxol). N Engl J Med. 1995;332:1004-1014.
11. Hortobagyi GN, Holmes FA, Theriault RL, Rahman Z, Buzdar AU. Combination chemotherapy with paclitaxel and doxorubicin for metastatic breast cancer. Semin Oncol. 1997;24:4(Suppl 11):11-19.
12. Martin M, Luch A, Ojeda B. Paclitaxel plus doxorubicin in metastatic breast cancer: preliminary analysis of cardiotoxicity. Semin Oncol. 1997;24:5(Suppl):17-30.
13. Carmichael J, Jones A, Hutchinson T. A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. United Kingdom Coordinating Committee for Cancer Research Breast Cancer Sub-Committee. Semin Oncol. 1997;24:5(Suppl 17):S17-S44.
14. Bristow Mr, Mason WJ, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med. 1978;88:168-175.
15. Lefrak EA, Pitha J, Rosenhelm S, O'Bryan RM, Burges MA, Gottlieb JA. Adriamycin cardiomyopthy. Cancer Chemother Rep. 1975;6:203-208.
16. Unverferth DV, Fetters JK, Unverferth BJ, et al. Human myocardial histologic characteristics in congestive heart failure. Circulation. 1983;68:1194-1200.
17. Innocenti F, Danesi R, Di-Paulo A. Plasma and tissue disposition of paclitaxel (taxol) after intraperitoneal administration in mice. Drug-Metab-Dispos. 1995;23:713-717.
18. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527-3561.
19. Gryglewski RJ, Botting RM, Vane JR. Mediators produced by the endothelial cell. Hypertension. 1988;12:530-548.
20. Schafer AI. Vascular endothelium: in defence of blood fluidity. J Clin Invest. 1997;99:1143.
21. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
22. McGorisk GM, Treasure CB. Endothelial function in coronary heart disease. Curr Opin Cardiol. 1996;311-341.
23. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990;47:219-231.
24. McGuire WP, Rowinsky EK, Rosenshien NB. A unique antineoplastic agent with significant activity in advanced overian epithelial neoplasms. Ann Intern Med. 1989;111:273-279.
25. Mailloux A, Grenet K, Bruneel A, Beneteau-Burnat B, Vaubourdolle M, Baudin B. Anticancer drugs induce necrosis of human endothelial cells involving both oncosis and apoptosis. Eur J Cell Biol. 200;80:442-449.